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Introduction
Atypical teratoid/rhabdoid tumor (ATRT) of the central 
nervous system (CNS) is a highly aggressive malignancy, 
accounting for 1%-2% of all pediatric CNS tumors [1,2]. 
Among children under the age of 3 years, ATRT constitutes 
the most common malignant tumor of CNS (17.3%), followed 
by medulloblastoma (16%) [3].
Since standard therapeutic strategies for ATRT have not 
been established yet, treatment approaches for ATRT vary 
among institutions and countries. Conventional chemother-
apy in addition to high-dose chemotherapy (HDCT) with 
autologous stem cell rescue (ASR) is usually utilized in pati-
ents under 3 years of age to substitute for or delay the use 
of radiotherapy (RT) in attempt to improve outcomes and 
minimize long-term neurocognitive impairment [4]. How-
ever, most patients with ATRT suffer rapid disease progres-
sion (PD), although treatment regimens designed for CNS 
neoplasms have been used [5,6]. Outcome for patients with 
ATRT is generally dismal, particularly in the presence of 
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Purpose  Atypical teratoid/rhabdoid tumor (ATRT) is a highly aggressive malignancy with peak incidence in children aged less than 3 
years. Standard treatment for central nervous system ATRT in children under the age of 3 years have not been established yet. The 
objective of this study was to analyze characteristics and clinical outcomes of ATRT in children aged less than 3 years.
Materials and Methods  A search of medical records from seven centers was performed between January 2005 and December 
2016.
Results  Forty-three patients were enrolled. With a median follow-up of 90 months, 27 patients (64.3%) showed at least one episode 
of disease progression (PD). The first date of PD was at 160 days after diagnosis. The 1- and 3-year progression-free survivals (PFS) 
were 51.2% and 28.5%, respectively. The 1- and 3-year overall survivals were 61.9% and 38.1%, respectively. The 3-year PFS was 
improved from 0% in pre-2011 to 47.4% in post-2011. Excluding one patient who did not receive any further therapy after surgery, 27 
patients died due to PD (n=21), treatment-related toxicity (n=5), or unknown cause (n=1). In univariate analysis, factors associated 
with higher 3-year PFS were no metastases, diagnosis after 2011, early adjuvant radiotherapy, and high-dose chemotherapy (HDCT). 
In multivariate analysis, the use of HDCT and adjuvant radiotherapy remained significant prognostic factors for PFS (both p < 0.01).   
Conclusion  Aggressive therapy including early adjuvant radiotherapy and HDCT could be considered to improve outcomes of ATRT 
in children under the age of 3 years. 
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residual tumor or metastasis. ATRT is a devastating brain 
neoplasm with a median survival time ranging from 6 to 13 
months. This is caused not only by the disease’s aggressive 
characteristics, but also by a lower tolerance of young pati-
ents to treatment. This is exacerbated by the hesitancy to use 
RT in younger patients due to risks of functional impairment 
of the developing brain [7]. It has been shown that aggres-
sive therapy can prolong survival in a subset of children with 
CNS ATRT [1,2,8]. Some clinical trials have incorporated early 
administration of RT to the primary site together with intra-
thecal (IT) chemotherapy, resulting in improved outcomes 
[9,10]. 
In 2005, the Korean Society for Pediatric Neuro-Oncology 
(KSPNO) suggested the following a protocol for ATRT pati-
ents aged less than 3 years (KSPNO-S052): six cycles of con-
ventional chemotherapy and tandem HDCT/ASR are per-
formed initially and RT is deferred until the patient reaches 
3 years of age. In 2008, a minor revision of the protocol inclu-
ding a dose modification of conventional chemotherapy was 
made (KSPNO-S082). In 2011, the protocol was revised (KSP-
NO-S1102) to recommended early local RT with concurrent 
chemotherapy within four weeks after surgery. In addition, 
IT chemotherapy was incorporated. 
Given the rarity of this tumor and the even lower number 
of very young infants affected by ATRT, no detailed clinical 
analyses have been directed toward patients under 3 years 
of age. Thus, the objective of this study was to describe pati-
ents diagnosed with ATRT in this age group and determine 
potential specific characteristics or prognostic factors. Their 
therapeutic management is also suggested.
Materials and Methods
1. Data collection
Children younger than 3 years of age at diagnosis who 
were newly diagnosed with CNS ATRT were eligible for 
this study. A search of medical records from seven centers 
was performed to identify patients aged 3 years or less who 
were diagnosed between January 2005 and December 2016. 
In cases with multiple intracranial and extracranial rhabdoid 
tumors, only patients with clear descriptions of a primary 
tumor within the CNS were included in this analysis. All 
participating centers received Institutional Review Board 
approval to contribute data for this study.
Fig. 1.  Treatment recommendations by the Korean Society for Pediatric Neuro-Oncology for CNS ATRT during periods of 2005-2007 (A), 
2008-2010 (B), and 2011-present (C). ASR, autologous stem cell rescue; CR, complete response; CSI, craniospinal irradiation; HDCT, high-
dose chemotherapy; IT, intrathecal; RT, radiotherapy. a)R0 (< 1.5 cm2)/M0, local RT 41.4 Gy; R+ (> 1.5 cm2)/M0, local RT 55.8 Gy; Rx/M+, 
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2. Staging
Proper staging for metastases included brain and spinal 
magnetic resonance imaging (MRI) and cytology of the cer-
ebrospinal fluid (CSF). Modified Chang status for metastatic 
stage was recorded whenever available. It was defined as fol-
lows: M0, absence of metastases; M1, presence of metastases 
confined to CSF; M2, presence of metastases in the brain; M3, 
presence of metastases in the spinal subarachnoidal space; 
and M4, spread outside of the CNS [11]. M+ included M1, 
M2, M3, M4, and any metastasis not further described.
3. Treatment
All patients underwent maximal possible surgical resec-
tion of the primary lesion to preserve neurologic function. 
The extent of surgical resection defined as gross total resec-
tion (GTR), subtotal resection, or biopsy was determined 
based on a review of postoperative MRI and the surgeon’s 
intraoperative assessment. Multimodal therapies includ-
ing surgery, RT, chemotherapy and HDCT/ASR were per-
formed. Treatment was mainly performed according to 
KSPNO recommendations. However, some physicians mod-
ified the treatment protocol depending on clinical situation. 
Treatment scheme of the KSPNO regimen is shown in Fig. 1. 
Major differences between KSPNO-S052/-S082 (pre-2011) 
and KSPNO-S1101 (post-2011) were the timing of RT (dela-
yed RT pre-2011 vs. early adjuvant RT post-2011) and IT 
chemotherapy for patients post-2011. Detailed chemothera-
py schedules are described in Table 1.
KSPNO-S052/S082 (pre-2011) suggested the following: 
Induction treatment was initiated within 4 weeks of surgery. 
Six cycles of chemotherapy using alternating CECV (cispl-
atin, etoposide, cyclophosphamide, and vincristine) and 
CEIV (carboplatin, etoposide, ifosfamide, and vincristine) 
regimens were administered. Additionally, tandem HDCT/
ASR was performed. The first course included carbopl-
atin, thiotepa and etoposide (CTE), and the second course 
included cyclophosphamide and melphalan (CM). A 12- to 
16-week interval between the first and second HDCT/ASR 
was allowed to minimize treatment-related mortality (TRM). 
RT was deferred until after 3 years of age unless the tumor 
showed progression or relapse. For patients with M0 disease 
at diagnosis and for patients those without residual tumor 
after HDCT, RT was omitted.
KSPNO-S1102 (post-2011) suggested the following: RT was 
Table 1.  Chemotherapy regimens
Regimen Drug Dose  Schedule
KSPNO-S052 induction chemotherapy
    Regimen a Cisplatin 3.5 mg/kg Day 0
 Etoposide 2.5 mg/kg Days 0, 1, and 2
 Cyclophosphamide 60 mg/kg Days 1 and 2
 Vincristine 0.05 mg/kg Days 0, 7, and 14
    Regimen b Carboplatin 10 mg/kg Days 0 and 1
 Etoposide 2.5 mg/kg Days 0 to 4
 Ifosfamide 60 mg/kg Days 0 to 4
 Vincristine  0.05 mg/kg Days 0, 7, and 14
KSPNO-S082/S1102 induction chemotherapy 
    Regimen A Cisplatin 3 mg/kg Day 0
 Etoposide 2.5 mg/kg Days 0, 1, and 2
 Cyclophosphamide 50 mg/kg Days 1 and 2
 Vincristine 0.05 mg/kg Days 0 and 7 
    Regimen B Carboplatin 10 mg/kg Days 0 and 1
 Etoposide 2.5 mg/kg Days 0 to 4
 Ifosfamide 50 mg/kg Days 0 to 4
 Vincristine  0.05 mg/kg Days 0 and 7
KSPNO-S052/S082/S1102 high-dose chemotherapy 
    First: CTE Carboplatin 500 mg/m2 Days –8 to –6
 Thiotepa 300 mg/m2 Days –5 to –3
 Etoposide 250 mg/m2 Days –5 to –3
    Second: CM Cyclophosphamide 1,500 mg/m2 Days –8 to –5
 Melphalan 60 mg/m2 Days –4 to –2
CM, cyclophosphamide and melphalan; CTE, carboplatin, thiotepa and etoposide.
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recommended to be administered within 4 weeks of surgery 
with concurrent chemotherapy. IT chemotherapy including 
cytarabine, hydrocortisone, and methotrexate (MTX) was 
administered on day 0 of every chemotherapy cycle. For M+ 
patients, weekly IT chemotherapy was administered until 
clearance of CSF cytology. After six cycles of alternating 
CECV and CEIV regimens, tandem HDCT/ASR using CTE-
CM was performed. For M+ patients at diagnosis, craniospi-
nal irradiation (CSI) was deferred at 3 years of age.
4. Response and toxicity criteria
Disease response was evaluated by MRI and CSF cytology. 
Evaluations were repeated every two or three chemotherapy 
cycles prior to the first HDCT/ASR, between the first and 
second HDCT/ASR, every 3 months for the first year after 
completion of tandem HDCT/ASR, every 4 months for the 
second year, and every 6 months thereafter. Disease response 
was categorized as follows: complete response (CR) for com-
plete disappearance of all tumors, partial response (PR) for 
decrease in tumor size by more than 50%, stable disease for 
less than 25% change in tumor size, PD for greater than 25% 
increase in tumor size or the appearance of new tumors. 
Toxicities were graded using the National Cancer Institute’s 
Common Terminology Criteria ver. 4.0.
5. Statistical analysis
The cutoff point for data analyses was March 2019. For 
descriptive statistics, data were compared using the Fisher 
exact test for categorical factors and Wilcoxon Mann-Whit-
ney U test for continuous factors. The time to progression 
was calculated from the date of diagnosis until the date of 
PD. Progression-free survival (PFS) was calculated from the 
date of diagnosis to the date of PD or relapse. Overall sur-
vival (OS) was calculated from the date of initial diagnosis to 
the date of last follow-up or death from any cause. PFS and 
OS were estimated using the Kaplan-Meier method. Univari-
ate analysis of risk factors was performed by comparing PFS 
and OS using the log-rank test. Multivariate logistic regres-
sion was used to examine relationships between outcomes of 
PFS or OS as binary dependent variables and independent 
variables of patient age, metastases, extent of resection, early 
adjuvant RT, HDCT, and years of diagnosis. p < 0.05 was con-
sidered statistically significant. All analyses were performed 
using IBM SPSS ver. 18.0 (SPSS Inc., Chicago, IL).
Results
1. Patient characteristics
Baseline clinical characteristics of patients are shown in 
Table 2. Forty-three patients were enrolled in this study. 
The median age at diagnosis was 13 months (range, 0 to 32 
months). Twenty patients (46.5%) were younger than 1 year 
of age at diagnosis. One patient presented with synchronous 
tumors, including ATRT in brain and a rhabdoid tumor in 
the kidney. 
Nineteen patients (44.2%) were diagnosed before 2011 (pre-
2011 group) and 24 patients (55.8%) were diagnosed after 
2011 (post-2011 group). There was no significant difference 
in age at diagnosis (p=0.55), sex (p=0.43), extent of resection 
Table 2.  Clinical characteristics of patients
 Pre-2011 (n=19) Post-2011 (n=24) Total (n=43)
Male:Female 9:10 13:11 22:21
Age at diagnosis (mo)
    Median (range) 13.0 (1-31) 14.5 (0-32) 13.0 (0-32)
    < 6 mo 4 (21.1) 5 (20.8) 9 (20.9)
    6-12 mo 5 (26.3) 6 (25.0) 11 (25.6)
    > 12 mo 10 (52.6) 13 (54.2) 23 (53.5)
Neuraxis metastasis
    M0 11 (57.9) 12 (50.0)  23 (53.5)
    M1 2 (10.5) 2 (8.3) 4 (9.3)
    M2 5 (26.3) 9 (37.5) 14 (32.6)
    Unknown 1 (5.3) 1 (4.2) 2 (4.7)
Type of resection
    Gross total resection 12 (63.2) 12 (50.0) 24 (55.8)
    Subtotal resection 6 (31.6) 12 (50.0) 18 (41.9)
    Biopsy 1 (5.3) 0 ( 1 (2.3)
Palliative care only after surgery 1 (5.3) 0 ( 1 (2.3)
Values are presented as number (%) unless otherwise indicated.
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(p=0.15), or metastases (p=0.46) between pre-2011 and post-
2011 groups. There were 23 (53.5%) patients with M0 disease, 
four (9.3%) with M1 disease, 14 (32.6%) with M2 disease, and 
two (4.7%) with unknown metastatic status. The incidence of 
metastatic disease was significantly higher in patients under 
6 months of age than that in patients older than 6 months 
(100.0% vs. 35.3%, p < 0.01). GTR of the primary tumor was 
achieved in 24 patients (55.8%). 
2. Treatment  
One patient did not receive any further therapy after sur-
gery. All remaining 42 patients received induction chemo-
therapy at a median of 20 days after surgery (range, 5 to 142 
days). The median number of pretransplant chemotherapy 
cycles was 6 (range, 1 to 12). All patients in the post-2011 
group received IT therapies. Nine patients (21.4%) received a 
second surgery before HDCT due to PD (n=8) or for remov-
ing residual tumor (n=1). 
Twenty-nine patients (69.0%) received radiation at a med-
ian age of 23 months (range, 6 to 40 months). The median 
interval between diagnosis and RT was 162 days (range, 21 
to 745 days). Thirteen patients (31.0%) did not receive RT due 
to early progression (n=8), treatment-related death (n=3), or 
physician’s discretion (n=2). As of 2011, RT timing changed 
from delayed RT (pre-2011) to early adjuvant RT (post-2011). 
As a result, the median period between diagnosis and RT was 
significantly shortened from 314.9 days in the pre-2011 group 
to 159.0 days in the post-2011 group (p=0.04). The period 
between diagnosis to RT was 114.6±104.8 days in patients 
who received early adjuvant RT and 313.4±231.2 days in 
patients who received RT as salvage therapy (p < 0.01).
Among 29 patients who received RT, early adjuvant RT was 
administered in 14 patients (2 in the pre-2011 group and 12 
in the post-2011 group) (Table 3). They received local RT 
at a dose of 36-63 Gy after surgery. Of them, five patients 
received additional CSI at a dose of 23.4-30.6 Gy concurrent-
ly (n=2) or at 3 years of age (n=3) due to M+ disease at diag-
nosis. Thirteen patients received local RT as salvage therapy 
Table 3.  Treatment and clinical outcomes 
 Pre-2011 (n=18) Post-2011 (n=24) Total (n=42)
Treatment
    Chemotherapy 18 (100) 24 (100) 42 (100)
    RT 12 (66.7) 17 (70.8) 29 (69.0)
        Early adjuvant local RT 2 (11.1) 12 (50.0) 14 (33.3)
            With concurrent CSI 1 ( 1 ( 2 (
            CSI at 3 years of age after completion of HDCT 0 ( 3 ( 3 (
        Salvage local RT at relapse/progression 9 (50.0) 4 (16.7) 13 (31.0)
            With concurrent CSI 4 ( 1 ( 5 (
            CSI at 3 years of age after completion of HDCT 1 ( 1 ( 2 (
        CSI at 3 year of age only 1 (5.5) 1 (4.2) 2 (4.8)
    HDCT 9 (50.0) 15 (62.5) 24 (57.1)
        1 HDCT 1 (5.6) 8 (33.3) 9 (21.4)
        2 HDCT 8 (44.4) 7 (29.2) 15 (35.8)
Response to treatment
    Continued response  3 (16.7) 12 (50.0) 15 (35.7)
    Disease progression  15 (83.3) 12 (50.0) 27 (64.3)
        After initial surgery 1 ( 2 ( 3 (
        During induction chemotherapy 9 ( 5 ( 14 (
        During RT 0 ( 1 ( 1 (
        During HDCT 0 ( 2 ( 2 (
        After completion of HDCT 5 ( 2 ( 7 (
Final outcome
    Alive without disease 4 (22.2) 11 (45.8) 15 (35.7)
    Alive with disease 0 ( 0 ( 0 (
    Death due to disease progression 11 (61.1) 10 (41.7) 21 (50.0)
    Treatment-related death 2 (11.1) 3 (12.5) 5 (11.9)
    Death due to unknown cause     1 (5.6) 0 ( 1 (2.4)
Values are presented as number (%). CSI, craniospinal irradiation; HDCT, high-dose chemotherapy; RT, radiotherapy.
Cancer Res Treat. 2021;53(2):378-388
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at a dose of 25.2-55.8 Gy. Of them, five patients received CSI 
at a dose of 19.5-23.4 Gy. Two patients received CSI at 3 years 
of age after completion of HDCT as scheduled. 
Twenty-four patients received HDCT/ASR (15 patients 
received tandem HDCTs and nine patients received only 1 
HDCT). Reasons not having second HDCT included physi-
cian’s discretion (n=4), PD or relapse (n=3), prolonged bone 
marrow suppression (n=1), and patient refusal (n=1). During 
the first HDCT, eight patients received conditioning regimen 
including topotecan, thiotepa, and carboplatin instead of 
CTE. During the second HDCT, two patients received con-
ditioning regimen including busulfan, melphalan, and thi-
otepa instead of CM. 
Significantly more patients who received early adjuvant 
RT proceeded to HDCT compared to patients who did not 
(78.6% vs. 46.4%, p=0.04). For patients not receiving HDCT 
(n=18), reasons included PD or relapse (n=12), treatment-
related death (n=4), patient refusal (n=1), and death due to 
unknown cause (n=1). The median age at the time of the 
first HDCT was 21.0 months (range, 9.1 to 44.5 months). The 
median time between diagnosis and the first HDCT was 7.5 
months (range, 5.3 to 16.1 months). Disease status before the 
first HDCT was CR in 16 and PR in eight. Among 15 patients 
who underwent a second HDCT, disease status before the 
second HDCT was CR in 10, PR in four, and PD in one. The 
median interval between the first and second HDCT was 91 
days (range, 35 to 126 days). 
3. Clinical course and survival
Excluding one patient who received palliative care only, 
data for 42 patients were analyzed (Table 3). With a median 
follow-up of 90 months (range, 27 to 172 months), 27 pati-
ents (64.3%) showed at least one episode of PD. The first date 
of PD was at 160 days (median; range, 13 to 585) after the 
diagnosis. Twenty-one of 27 patients who showed PD died 
due to PD at a median of 4 months (range, 0.1 to 5.4 months) 
from the first day of documentation of PD. Immediate sal-
vage therapy consisted of surgery in 11, chemotherapy in 
four, RT in four, gamma knife surgery in one, and support-
ive care only in seven. PD was found within 2 months of 
resection surgery before initiation of chemotherapy in three, 
during chemotherapy in 14, during adjuvant RT in one, dur-
ing HDCT in two, and after completion of HDCT in seven. 
Among 14 patients with PD found during induction chem-
otherapy, 13 did not receive adjuvant RT previously while 
one patient had received RT previously (p < 0.01). Of nine 
patients who experienced relapse during or after HDCT, 
seven patients died due to PD. Two patients are still alive 
without disease. The median time between HDCT and sub-
sequent relapse was 3 months (range, 1 to 11 months).
The 1- and 3-year PFS is 51.2% and 28.5%, respectively. The 
1- and 3-year OS is 61.9% and 38.1%, respectively (Fig. 2). 
Of 42 patients analyzed, 27 patients died due to PD (n=21), 
treatment-related toxicity (n=5), or unknown causes (n=1).
At the last follow-up, 15 patients were alive. All surviving 
patients received HDCT/ASR. Patients who achieved CR 
before the first HDCT showed significantly higher 3-year OS 
compared to patients who did not (81.3% vs. 37.5%, p < 0.01). 
There was no significant difference in PFS or OS between 
patients who underwent 1 HDCT and those who underwent 
2 HDCTs.
4. Risk factors 
Results of univariate and multivariate analyses for PFS are 
shown in Table 4. In univariate analysis, factors associated 
with higher 3-year PFS were no metastases (p=0.03), diag-
nosis after 2011 (p=0.04), early adjuvant RT (p < 0.01) and 
HDCT/ASR (p < 0.01) (Fig. 3). Age at diagnosis (p=0.53) and 
extent of resection (p=0.29) failed to influence survival rate 
in our study. Among 14 patients who received adjuvant RT, 
only three patients showed PD during (n=1) or after (n=2) 
the planned RT, while 24 of 28 patients who did not receive 
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Table 4.  Univariate and multivariate analysis of the probability of progression-free survival 
                               Univariate                                Multivariatea)
 HR (95% CI) p-value HR (95% CI) p-value
Years of diagnosis    
    Pre-2011 1 ( 0.04 1 ( 0.57 
    Post-2011 0.47 (0.23-0.96)  0.81 (0.44-1.62) 
Patient age (yr)
    < 1  1 ( 0.53
    ≥ 1  0.79 (0.39-1.59)    
Metastases    
    Yes  1 ( 0.03 1 ( 0.53
    No 0.46 (0.23-0.90)  0.85 (0.43-1.59)  
Extent of resection  
    GTR 1 ( 0.29
    No GTR 1.23 (0.56-2.27)   
Early adjuvant RT    
    Yes 1 ( < 0.01 1 ( < 0.01
    No 5.68 (2.14-15.12)  6.42 (2.29-17.90) 
HDCT  
    Yes 1 ( < 0.01 1 ( < 0.01
    No 10.26 (3.81-27.66)  12.0 (3.91-37.28)  
 CI, confidence interval; GTR, gross total resection; HDCT, high-dose chemotherapy; HR, hazard ratio; RT, radiotherapy. a)Includes vari-
ables significant at  p < 0.1 (overall) in univariate analysis.
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HDCT (+) (n=24): 3-yr PFS 41.7%±10.1%
HDCT (–) (n=18): 1-yr PFS 13.8%±9.0%
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adjuvant RT showed PD (p < 0.01). Among 18 patients with 
metastases, patients who received early adjuvant local RT 
showed significantly higher PFS and OS compared to those 
who did not (3-year PFS: 75.0% vs. 0%, p=0.04; 3-year OS: 
75.0% vs. 14.3%, p=0.03).
In multivariate analyses, the use of HDCT/ASR and early 
adjuvant RT remained significant prognostic factors for PFS 
(both p < 0.01). For OS, the use of HDCT/ASR was the only 
significant prognostic factor (p < 0.01). Among patients who 
received both early adjuvant RT and HDCT/ASR, 3-year PFS 
and OS were 81.8% and 90.9%, respectively. 
 
5. Toxicity
During chemotherapy, the most frequently reported sig-
nificant toxicities were bone marrow suppression and febrile 
neutropenia followed by infection, gastrointestinal distur-
bances, electrolyte disturbances, and hepatic disturbances. 
During HDCT, infection was the most common toxicity. Bac-
teremia was detected during six of 39 HDCT (3 Staphylococcus 
epidermidis, 2 Pseudomonas aeruginosa, and 1 Bacillus species), 
five of which occurred during the second HDCT course. One 
patient experienced sinusoidal obstruction syndrome dur-
ing their second HDCT. There were five toxic deaths due to 
sepsis: four occurred under chemotherapy and one occurred 
following the second HDCT. To date, second malignancies 
have not been reported.
Discussion
This is the most recent update of Korean ATRT patients 
under 3 years of age. Tumors progressed or relapsed in 27 
of 42 patients at a median of 160 days from diagnosis in our 
study. The 3-year PFS and OS were 28.5% and 38.1%, respec-
tively. The 3-year PFS was improved from 0.0% in pre-2011 
to 47.4% in post-2011. At diagnosis, metastasis was the only 
characteristic among several disease characteristics known 
to affect survival. 
Our analysis highlights several points of interest for this 
young age group. First, our data suggest the importance of 
early adjuvant RT. We found a survival benefit associated 
with early adjuvant RT. Traditionally, RT has been deferred 
or omitted because of the risk of adverse effects, especially for 
patients under 3 years of age [12]. However, more recent data 
suggest that RT might be more efficacious than chemothera-
py for ATRT patients, even for very young children [2,13,14]. 
In a previously reported Korean study that included patients 
treated with tandem HDCT/ASR, all surviving patients 
received RT at an early stage in their treatment [15]. No 
patients who received induction chemotherapy and HDCT/
ASR without RT survived. This suggests that HDCT/ASR 
cannot replace RT for local control. Similarly, we found that 
patients who received early adjuvant RT showed a signifi-
cantly lower chance of having PD during induction chemo-
therapy and a higher chance to proceed to HDCT compared 
to patients who did not, thus leading to improved survival. 
For patients with M+ disease at diagnosis, adjuvant local 
radiation significantly improved survival in the current 
study. Overall, local RT should be considered earlier in ther-
apy to improve survival.
Secondly, our data suggest that HDCT is associated with 
better survival. For patients who received HDCT, PFS and 
OS were significantly higher compared to those who did not. 
There has been no randomized study to evaluate the efficacy 
of HDCT/ASR in ATRT patients under 3 years of age. A few 
studies have suggested that HDCT might have a favorable 
effect on ATRT patients [14,16]. A recent Canadian study has 
reported better 5-year PFS in patients with ATRT under 1 
year of age receiving HDCT group compared to those with-
out receiving HDCT (50.1% vs. 11.3%, p < 0.001) [17]. How-
ever, due to small numbers of patients included and various 
treatment modalities used, no firm conclusions can be made 
regarding the role of HDCT/ASR in ATRT patients. In this 
study, all surviving patients received HDCT/ASR. Howev-
er, this does not reflect the definite efficacy of HDCT/ASR. 
Considering that patients who achieved CR before their first 
HDCT showed significantly higher OS than those who did 
not, multimodal treatment that might lead to CR and addi-
tional HDCT might result in better outcomes. In this study, 
patients who achieved CR before the first HDCT showed 
significantly higher OS. This suggests that pre-HDCT tumor 
status is important for predicting outcome. Thus, careful 
consideration is required when selecting candidate patients 
for HDCT/ASR.
Importantly, we should consider the likelihood of selection 
bias toward “favorable cases” in patients subjected to HDCT, 
which could be associated with molecular distinction. Recen-
tly, Reddy et al. [18] have reported that patients with group 
1/SHH-NOTCH tumors have less aggressive feature. Bio-
logical investigation of ATRT should be continued and sub-
sets of patients who can be cured with less therapy may exist 
[19].
The optimal combination of regimens for tandem HDCT 
has not been determined. Rosenfeld et al. [12] have reported 
the feasibility of tandem HDCT/ASR in patients with brain 
tumors using CTE-CM. Although they concluded that the 
CTE-CM regimen was not feasible due to toxicity, tandem 
CTE-CM HDCT/ASR was feasible in our study. Toxicities in 
our present study were manageable and only one toxic death 
associated with HDCT occurred. This could be due to the 
fact that patients were given a sufficient rest period between 
the first and the second HDCT/ASR. Sung et al. [20] have 
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reported that a shorter interval (< 12 weeks) between the 
first and second HDCT/ASR is associated with higher TRM. 
Another thing to be noted was that there was no significant 
survival difference between patients who received 1 HDCT 
and those who received 2 HDCTs. In addition, bacteremia 
occurred more frequently in the second HDCT than in the 
first HDCT. Randomized trials with larger cohorts are need-
ed to determine whether the possible survival benefit of tan-
dem HDCT/ASR over single HDCT/ASR might ultimately 
outweigh adverse effects associated with dose intensive tan-
dem HDCT/ASR.
Thirdly, optimal induction chemotherapy should be explo-
red. Efficacies of many different treatments have been explo- 
red. However, there is no consensus regarding standard 
chemotherapy for ATRT. Due to the desire to avoid unaccep-
table adverse effects of RT on the developing brain, many 
institutions adopt chemotherapy-based strategies designed 
to avoid or delay RT. Despite often impressive responses to 
chemotherapy, the majority of patients in many published 
studies developed progressive disease early, suggesting a 
rapid development of resistance of ATRTs [10,21,22]. Similar-
ly, in our study, PD occurred during induction chemotherapy 
in about half of cases. Considering that the most common 
reason not having HDCT/ASR was PD during induction 
chemotherapy, we could consider shorten the current six 
cycles of induction chemotherapy. Furthermore, patients 
who received induction chemotherapy without early adju-
vant RT showed significantly lower survival compared to 
patients who received early adjuvant RT. This suggests that 
CECV and CEIV chemotherapy regimen used in our patients 
might be insufficient to prevent tumor progression/relapse. 
Recently, ACNS0333 comprised with three cycles of chemo-
therapy which incorporated high dose MTX showed promis-
ing result, with 4-year OS of 43% [18]. High-dose MTX used in 
“Head Start II” also appears to be efficacious and well toler-
ated in ATRT [8]. Slavc et al. [23] have also demonstrated the 
efficacy of high-dose MTX in ATRT patients. Besides intensi-
fication using cytotoxic agent, there are increasing data sug-
gesting that ATRT might be a good candidate for pathway-
specific targeted therapies, some of which are currently used 
in clinical trials, including AURKA, EZH2, and CDK4/6 inhi- 
bitors [24,25]. Optimwal combination of cytotoxic agents and 
targeted inhibitors should be explored to prevent early pro-
gression of ATRT.
Lastly, we found that the post-2011 group had signifi-
cantly better PFS than the pre-2011 group. The major dif-
ference between pre- and post-2011 protocols was adjuvant 
local radiation and IT chemotherapy in the post-2011 pro-
tocol. There was no difference in induction chemotherapy 
or HDCT between pre- and post-2011 protocols. We believe 
that the post-2011 protocol with a combination of adjuvant 
RT and IT chemotherapy might have prevented early pro-
gression, eventually improving the outcome as reported 
by Chi et al. [10]. The role of adjuvant RT has already been 
described above. IT therapy was incorporated as a method of 
providing prophylaxis and/or treatment to the CNS axis in 
the post-2011 protocol. Whether IT therapy could substitute 
for cranial irradiation for CNS treatment and/or prophylaxis 
was unclear because both modalities were used in the post-
2011 protocol. Considering that the year of diagnosis (pre- vs. 
post-2011) was not a significant predictor of survival in mul-
tivariate analyses, IT therapy might not have a beneficial role 
in improving survival. However, in many studies, IT chemo-
therapy has shown potential benefit as an addition to local 
RT or to intensify therapy in patients who are not candidates 
for CSI [10,26]. IT chemotherapy shows good penetrance into 
the CSF. Thus, it might be efficacious in eradicating ATRT 
cells in CSF, allowing postponement of CSI for patients who 
receive focal irradiation only. A meta-analysis by Athale et al. 
[26] has shown that IT therapy leads to a significantly higher 
OS. A more detailed randomized study I needed to evaluate 
IT therapy in infant ATRT to define role of IT therapy in these 
patients.
This study has some limitations. First, this study had a 
non-randomized and retrospective design. Second, we did 
not collect data for germline mutations in SMARCB1/INI1. 
Therefore, we could not assess the association between ger-
mline status and outcome. No molecular profiling was inclu-
ded, which could be potential prognostic indicators. Third, 
because current multimodality treatment strategies for ATRT 
include brain RT, limited data on neurocognitive outcomes 
of survivors raise a significant concern [27]. Although data 
stress the importance for RT in younger age group, this treat-
ment option comes at a cost of serious long-term sequelae 
such as cognitive, motor, visual, and hearing impairment 
[28,29]. In addition, combining multimodal treatment deser- 
ves attention. Comprehensive long-term follow-up neuro-
psychologic assessments are planned for our surviving 
cohort. Lastly, as described above, a more detailed analysis is 
needed in the future to identify the role of IT therapy in the 
prevention and treatment of metastases.
In summary, aggressive therapy including early adminis-
tration of local RT and HDCT/ASR, which was adopted in 
KSPNO-S1102, should be considered to improve outcomes of 
ATRT in children below the age of 3 years. Despite the high 
probability of early PD in ATRT, for patients who received 
both early adjuvant RT and HDCT/ASR, OS exceeded 90%. 
Further clinical trials may be required to determine optimal 
adjuvant treatments such as RT field and intensity of HDCT/
ASR and the role of IT chemotherapy for patients with ATRT. 
Future studies regarding molecular characterization of ATRT 
and its prognostic implication might change current treat-
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ment strategies and delineate the group of patients so that 
treatment intensity could be reduced.
Ethical Statement 
Ethics approval and consent to participation: All participating cent-
ers received Institutional Review Board approval to contribute data 
for this study (NCC 2018-0210). This study was performed in accor-
dance with the Declaration of Helsinki.
Author Contributions
Conceived and designed the analysis: Park M, Han JW, Park HJ.
Collected the data: Park M, Han JW, Hahn SM, Lee JA, Kim JY, Shin 
SH, Kim DS, Yoon HI, Hong KT, Choi JY, Kang HJ, Shin HY, Phi JH, 
Kim SK, Lee JW, Yoo KH, Sung KW, Koo HH, Lim DH, Shin HJ, 
Kim H, Koh KN, Im HJ, Ahn SD, Ra YS, Baek HJ, Kook H, Jung TY, 
Choi HS, Kim CY, Park HJ, Lyu CJ.
Contributed data or analysis tools: Park M.
Performed the analysis: Park M.
Wrote the paper: Park M. 
Review the paper: Lyu CJ, Park HJ. 
Conflicts of Interest
Conflicts of interest relevant to this article was not reported.
Acknowledgments
This study was supported by the KPHOG Research Grant 2018.
1.  Hilden JM, Meerbaum S, Burger P, Finlay J, Janss A, Scheithau-
er BW, et al. Central nervous system atypical teratoid/rhab-
doid tumor: results of therapy in children enrolled in a regis-
try. J Clin Oncol. 2004;22:2877-84.
2.  Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Mer-
chant TE, et al. Atypical teratoid/rhabdoid tumors (ATRT): 
improved survival in children 3 years of age and older with 
radiation therapy and high-dose alkylator-based chemother-
apy. J Clin Oncol. 2005;23:1491-9.
3.  Woehrer A, Slavc I, Waldhoer T, Heinzl H, Zielonke N, Czech 
T, et al. Incidence of atypical teratoid/rhabdoid tumors in 
children: a population-based study by the Austrian Brain 
Tumor Registry, 1996-2006. Cancer. 2010;116:5725-32.
4.  Cohen BH, Geyer JR, Miller DC, Curran JG, Zhou T, Holmes 
E, et al. Pilot study of intensive chemotherapy with peripheral 
hematopoietic cell support for children less than 3 years of 
age with malignant brain tumors, the CCG-99703 phase I/II 
study: a report from the Children’s Oncology Group. Pediatr 
Neurol. 2015;53:31-46.
5.  Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner 
JL, et al. Atypical teratoid/rhabdoid tumor of the central nerv-
ous system: a highly malignant tumor of infancy and child-
hood frequently mistaken for medulloblastoma: a Pediatric 
Oncology Group study. Am J Surg Pathol. 1998;22:1083-92.
6.  Weiss E, Behring B, Behnke J, Christen HJ, Pekrun A, Hess CF. 
Treatment of primary malignant rhabdoid tumor of the brain: 
report of three cases and review of the literature. Int J Radiat 
Oncol Biol Phys. 1998;41:1013-9.
7.  Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. 
Late neurocognitive sequelae in survivors of brain tumours 
in childhood. Lancet Oncol. 2004;5:399-408.
8.  Gardner SL, Asgharzadeh S, Green A, Horn B, McCowage G, 
Finlay J. Intensive induction chemotherapy followed by high 
dose chemotherapy with autologous hematopoietic progeni-
tor cell rescue in young children newly diagnosed with cen-
tral nervous system atypical teratoid rhabdoid tumors. Pedi-
atr Blood Cancer. 2008;51:235-40.
9.  Pai Panandiker AS, Merchant TE, Beltran C, Wu S, Sharma S, 
Boop FA, et al. Sequencing of local therapy affects the pattern 
of treatment failure and survival in children with atypical 
teratoid rhabdoid tumors of the central nervous system. Int J 
Radiat Oncol Biol Phys. 2012;82:1756-63.
10.  Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel 
JA, et al. Intensive multimodality treatment for children with 
newly diagnosed CNS atypical teratoid rhabdoid tumor. J 
Clin Oncol. 2009;27:385-9.
11.  Chang CH, Housepian EM, Herbert C Jr. An operative staging 
system and a megavoltage radiotherapeutic technic for cer-
ebellar medulloblastomas. Radiology. 1969;93:1351-9.
12.  Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Wein-
stein J, et al. A phase II prospective study of sequential mye-
loablative chemotherapy with hematopoietic stem cell rescue 
for the treatment of selected high risk and recurrent central 
nervous system tumors. J Neurooncol. 2010;97:247-55.
13.  Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, 
et al. Impact of radiotherapy for pediatric CNS atypical tera-
toid/rhabdoid tumor (single institute experience). Int J Radiat 
Oncol Biol Phys. 2006;64:1038-43.
14.  Lee JY, Kim IK, Phi JH, Wang KC, Cho BK, Park SH, et al. 
Atypical teratoid/rhabdoid tumors: the need for more active 
therapeutic measures in younger patients. J Neurooncol. 2012; 
107:413-9.
15.  Sung KW, Lim DH, Yi ES, Choi YB, Lee JW, Yoo KH, et al. 
Tandem high-dose chemotherapy and autologous stem cell 
transplantation for atypical teratoid/rhabdoid tumor. Cancer 
Res Treat. 2016;48:1408-19.
16.  Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, et al. 
Intensive induction chemotherapy followed by myeloabla-
tive chemotherapy with autologous hematopoietic progenitor 
cell rescue for young children newly-diagnosed with central 
nervous system atypical teratoid/rhabdoid tumors: the Head 
Start III experience. Pediatr Blood Cancer. 2014;61:95-101.
References
Meerim Park, ATRT in Children under the Age of 3 
VOLUME 53 NUMBER 2 APRiL 2021     387
17.  Fossey M, Li H, Afzal S, Carret AS, Eisenstat DD, Fleming A, 
et al. Atypical teratoid rhabdoid tumor in the first year of life: 
the Canadian ATRT registry experience and review of the lit-
erature. J Neurooncol. 2017;132:155-62.
18.  Reddy AT, Strother DR, Judkins AR, Burger PC, Pollack IF, 
Krailo MD, et al. Efficacy of high-dose chemotherapy and 
three-dimensional conformal radiation for atypical teratoid/ 
rhabdoid tumor: a report from the Children’s Oncology 
Group Trial ACNS0333. J Clin Oncol. 2020;38:1175-85.
19.  Richardson EA, Ho B, Huang A. Atypical teratoid rhabdoid 
tumour: from tumours to therapies. J Korean Neurosurg Soc. 
2018;61:302-11.
20.  Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, et al. 
Tandem high-dose chemotherapy and autologous stem cell 
rescue in patients over 1 year of age with stage 4 neuroblas-
toma. Bone Marrow Transplant. 2007;40:37-45.
21.  Ginn KF, Gajjar A. Atypical teratoid rhabdoid tumor: current 
therapy and future directions. Front Oncol. 2012;2:114.
22.  Lafay-Cousin L, Hawkins C, Carret AS, Johnston D, Zelcer 
S, Wilson B, et al. Central nervous system atypical teratoid 
rhabdoid tumours: the Canadian Paediatric Brain Tumour 
Consortium experience. Eur J Cancer. 2012;48:353-9.
23.  Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, 
et al. Atypical teratoid rhabdoid tumor: improved long-term 
survival with an intensive multimodal therapy and delayed 
radiotherapy. The Medical University of Vienna Experience 
1992-2012. Cancer Med. 2014;3:91-100.
24.  Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, et 
al. Profiling pathway-specific novel therapeutics in preclini-
cal assessment for central nervous system atypical teratoid 
rhabdoid tumors (CNS ATRT): favorable activity of targeting 
EGFR- ErbB2 signaling with lapatinib. Mol Oncol. 2013;7:497-
512.
25.  Venneti S, Le P, Martinez D, Eaton KW, Shyam N, Jordan-
Sciutto KL, et al. p16INK4A and p14ARF tumor suppressor 
pathways are deregulated in malignant rhabdoid tumors. J 
Neuropathol Exp Neurol. 2011;70:596-609.
26.  Athale UH, Duckworth J, Odame I, Barr R. Childhood atypi-
cal teratoid rhabdoid tumor of the central nervous system: 
a meta-analysis of observational studies. J Pediatr Hematol 
Oncol. 2009;31:651-63.
27.  Lafay-Cousin L, Fay-McClymont T, Johnston D, Fryer C, 
Scheinemann K, Fleming A, et al. Neurocognitive evaluation 
of long term survivors of atypical teratoid rhabdoid tumors 
(ATRT): the Canadian registry experience. Pediatr Blood Can-
cer. 2015;62:1265-9.
28.  Duffner PK, Cohen ME. Long-term consequences of CNS 
treatment for childhood cancer, Part II: Clinical consequenc-
es. Pediatr Neurol. 1991;7:237-42.
29.  Hasan A, Palumbo M, Atkinson J, Carret AS, Farmer JP, 
Montes J, et al. Treatment-related morbidity in atypical tera-
toid/rhabdoid tumor: multifocal necrotizing leukoencepha-
lopathy. Pediatr Neurosurg. 2011;47:7-14.
388     CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2021;53(2):378-388
